<DOC>
	<DOCNO>NCT00195039</DOCNO>
	<brief_summary>The purpose study find effective 177Lu -J591 treatment patient metastatic , androgen-independent prostate cancer .</brief_summary>
	<brief_title>Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS ( 177Lu-J591 ) Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>To determine clinical activity 177Lu -J591 treatment patient metastatic , androgen-independent prostate cancer . Patients receive single dose J591 ( total antibody 20 mg ) consist antibody chelate 177Lu dose 65 70 mCi/m2 specific activity 12-15 mCi/mg plus non-radiolabeled antibody .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologic diagnosis prostate adenocarcinoma . Metastatic prostate cancer progressive image study and/or rise PSA despite adequate medical surgical castration therapy . Progressed follow discontinuation antiandrogen therapy , receive . Serum testosterone &lt; 50 ng/ml Use corticosteroid and/or adrenal hormone inhibitor within 4 week treatment . Use PCSPES within 4 week treatment . Use red blood cell platelet transfusion within 4 week treatment . Use hematopoietic growth factor within 4 week treatment . Prior cytotoxic chemotherapy and/or radiation therapy within 4 week treatment . Bone scan demonstrate confluent lesion involve axial appendicular skeleton . Prior radiation therapy encompass &gt; 25 % skeleton . Prior treatment 89Strontium 153Samarium contain compound ( e.g . Metastron® , Quadramet® ) . Active angina pectoris NY Heart Association Class IIIIV . History deep vein thrombophlebitis and/or pulmonary embolus within 3 month study entry . Other serious illness ( e ) involve cardiac , respiratory , CNS , renal , hepatic hematological organ system might preclude completion study interfere determination causality adverse effect experience study . Prior monoclonal antibody therapy exception ProstaScint® Prior investigational therapy ( medication device ) within 6 week treatment . Known history HIV</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>